ID: ALA3128170

Max Phase: Preclinical

Molecular Formula: C45H47N9O3

Molecular Weight: 761.93

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CN(C)[C@@H](C(=O)N1CCC[C@H]1c1nc2cc(-c3cnc(-c4ccc5[nH]c([C@@H]6CCCN6C(=O)[C@@H](c6ccccc6)N(C)C)nc5c4)o3)ccc2[nH]1)c1ccccc1

Standard InChI:  InChI=1S/C45H47N9O3/c1-51(2)39(28-13-7-5-8-14-28)44(55)53-23-11-17-36(53)41-47-32-21-19-30(25-34(32)49-41)38-27-46-43(57-38)31-20-22-33-35(26-31)50-42(48-33)37-18-12-24-54(37)45(56)40(52(3)4)29-15-9-6-10-16-29/h5-10,13-16,19-22,25-27,36-37,39-40H,11-12,17-18,23-24H2,1-4H3,(H,47,49)(H,48,50)/t36-,37-,39+,40+/m0/s1

Standard InChI Key:  TZDXGMWKFZFYGY-HTNZGVODSA-N

Associated Targets(Human)

Huh-7 12904 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Bovine viral diarrhea virus 1 1277 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Hepatitis C virus 23859 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 761.93Molecular Weight (Monoisotopic): 761.3802AlogP: 7.69#Rotatable Bonds: 10
Polar Surface Area: 130.49Molecular Species: NEUTRALHBA: 8HBD: 2
#RO5 Violations: 2HBA (Lipinski): 12HBD (Lipinski): 2#RO5 Violations (Lipinski): 3
CX Acidic pKa: 10.52CX Basic pKa: 7.57CX LogP: 5.45CX LogD: 4.97
Aromatic Rings: 7Heavy Atoms: 57QED Weighted: 0.15Np Likeness Score: -0.75

References

1. Belema M, Nguyen VN, Romine JL, St Laurent DR, Lopez OD, Goodrich JT, Nower PT, O'Boyle DR, Lemm JA, Fridell RA, Gao M, Fang H, Krause RG, Wang YK, Oliver AJ, Good AC, Knipe JO, Meanwell NA, Snyder LB..  (2014)  Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.,  57  (5): [PMID:24437689] [10.1021/jm4016203]
2. Ivachtchenko AV, Mitkin OD, Yamanushkin PM, Kuznetsova IV, Bulanova EA, Shevkun NA, Koryakova AG, Karapetian RN, Bichko VV, Trifelenkov AS, Kravchenko DV, Vostokova NV, Veselov MS, Chufarova NV, Ivanenkov YA..  (2014)  Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).,  57  (18): [PMID:25148100] [10.1021/jm500951r]

Source